STML Key Stats
- Stemline Cribs Cancer Patient Message Boards to Promote Stock The Street Dec 3
- Stemline (STML) Moves Higher; Will Make Five Presentations at 2013 ASH Annual Meeting Street Insider Nov 14
- Aegis Capital Sees Stemline (STML) ASH Data as Significant Value-Driving Catalysts Street Insider Nov 14
- BG Medicine (BGMD) Scoops-Up Stemline's (STML) Hall as CFO Street Insider Nov 14
- Oversold Conditions For Stemline Therapeutics (STML) Nov 12
- Aegis Capital Nearly Raises PT on Stemline (STML) to $70 Following Preclinical SL-401 Data Street Insider Oct 30
- Stemline Therapeutics (STML) Files to Withdraw S-1 Street Insider Oct 23
- Stemline Therapeutics Becomes Oversold (STML) Oct 22
- Stemline Therapeutics (STML) Files $90M Common Shelf Street Insider Oct 17
- Stemline initiated with an Outperform at Wedbush Sep 12
STML Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Stemline Therapeutics Inc is up N/A over the last year vs S&P 500 Total Return up 30.90%, Sarepta Therapeutics down 34.52%, and Albany Molecular Research up 101.5%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Balance Sheet View Statement
Pro Ratings for STML
Pro Strategies Featuring STML
Did Stemline Therapeutics Inc make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.